Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects

Naoyuki Yamada, Naoyuki Morishige, Ryoji Yanai, Yukiko Morita, Kazuhiro Kimura, Tai Ichiro Chikama, Motoyoshi Nomizu, Koh Hei Sonoda, Teruo Nishida

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: We have previously shown that the fibronectin-derived peptide PHSRN (Pro-His-Ser-Arg-Asn) promotes corneal epithelial wound healing in vivo. We have now examined the clinical efficacy of eye drops containing the PHSRN peptide for treatment of persistent epithelial defects (PEDs) of the cornea. Methods: Seven patients (5 men and 2 women; mean age ± SD, 78.3 ± 9.4 years) with PEDs were treated by administration of eye drops containing PHSRN. The duration of the PEDs before treatment was 7.4 ± 5.5 weeks. The eye drops were administered as 1 drop per eye 4 times a day. Epithelial defects were observed with a slit-lamp microscope and photographed during the treatment course. Results: Epithelial defects in 5 of the 7 affected eyes (71%) responded to PHSRN treatment as manifested by complete epithelial resurfacing within the 4-week period after treatment initiation. The mean ± SD time required for complete epithelial resurfacing in the 5 responding subjects was 15.8 ± 3.4 days. No adverse effects of treatment were observed in any of the subjects. Conclusions: Eye drops containing the fibronectin-derived PHSRN peptide are clinically efficacious for the treatment of PEDs.

Original languageEnglish
Pages (from-to)1408-1413
Number of pages6
JournalCornea
Volume31
Issue number12
DOIs
Publication statusPublished - Dec 1 2012
Externally publishedYes

Fingerprint

prolyl-histidyl-seryl-arginyl-asparagine
Ophthalmic Solutions
Fibronectins
Peptides
Therapeutics
Clinical Studies
Wound Healing
Cornea

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Yamada, N., Morishige, N., Yanai, R., Morita, Y., Kimura, K., Chikama, T. I., ... Nishida, T. (2012). Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects. Cornea, 31(12), 1408-1413. https://doi.org/10.1097/ICO.0b013e31824afd6c

Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects. / Yamada, Naoyuki; Morishige, Naoyuki; Yanai, Ryoji; Morita, Yukiko; Kimura, Kazuhiro; Chikama, Tai Ichiro; Nomizu, Motoyoshi; Sonoda, Koh Hei; Nishida, Teruo.

In: Cornea, Vol. 31, No. 12, 01.12.2012, p. 1408-1413.

Research output: Contribution to journalArticle

Yamada, N, Morishige, N, Yanai, R, Morita, Y, Kimura, K, Chikama, TI, Nomizu, M, Sonoda, KH & Nishida, T 2012, 'Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects', Cornea, vol. 31, no. 12, pp. 1408-1413. https://doi.org/10.1097/ICO.0b013e31824afd6c
Yamada, Naoyuki ; Morishige, Naoyuki ; Yanai, Ryoji ; Morita, Yukiko ; Kimura, Kazuhiro ; Chikama, Tai Ichiro ; Nomizu, Motoyoshi ; Sonoda, Koh Hei ; Nishida, Teruo. / Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects. In: Cornea. 2012 ; Vol. 31, No. 12. pp. 1408-1413.
@article{b2caf8ea5e184ecf9fc6109aa20374a8,
title = "Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects",
abstract = "Purpose: We have previously shown that the fibronectin-derived peptide PHSRN (Pro-His-Ser-Arg-Asn) promotes corneal epithelial wound healing in vivo. We have now examined the clinical efficacy of eye drops containing the PHSRN peptide for treatment of persistent epithelial defects (PEDs) of the cornea. Methods: Seven patients (5 men and 2 women; mean age ± SD, 78.3 ± 9.4 years) with PEDs were treated by administration of eye drops containing PHSRN. The duration of the PEDs before treatment was 7.4 ± 5.5 weeks. The eye drops were administered as 1 drop per eye 4 times a day. Epithelial defects were observed with a slit-lamp microscope and photographed during the treatment course. Results: Epithelial defects in 5 of the 7 affected eyes (71{\%}) responded to PHSRN treatment as manifested by complete epithelial resurfacing within the 4-week period after treatment initiation. The mean ± SD time required for complete epithelial resurfacing in the 5 responding subjects was 15.8 ± 3.4 days. No adverse effects of treatment were observed in any of the subjects. Conclusions: Eye drops containing the fibronectin-derived PHSRN peptide are clinically efficacious for the treatment of PEDs.",
author = "Naoyuki Yamada and Naoyuki Morishige and Ryoji Yanai and Yukiko Morita and Kazuhiro Kimura and Chikama, {Tai Ichiro} and Motoyoshi Nomizu and Sonoda, {Koh Hei} and Teruo Nishida",
year = "2012",
month = "12",
day = "1",
doi = "10.1097/ICO.0b013e31824afd6c",
language = "English",
volume = "31",
pages = "1408--1413",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects

AU - Yamada, Naoyuki

AU - Morishige, Naoyuki

AU - Yanai, Ryoji

AU - Morita, Yukiko

AU - Kimura, Kazuhiro

AU - Chikama, Tai Ichiro

AU - Nomizu, Motoyoshi

AU - Sonoda, Koh Hei

AU - Nishida, Teruo

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Purpose: We have previously shown that the fibronectin-derived peptide PHSRN (Pro-His-Ser-Arg-Asn) promotes corneal epithelial wound healing in vivo. We have now examined the clinical efficacy of eye drops containing the PHSRN peptide for treatment of persistent epithelial defects (PEDs) of the cornea. Methods: Seven patients (5 men and 2 women; mean age ± SD, 78.3 ± 9.4 years) with PEDs were treated by administration of eye drops containing PHSRN. The duration of the PEDs before treatment was 7.4 ± 5.5 weeks. The eye drops were administered as 1 drop per eye 4 times a day. Epithelial defects were observed with a slit-lamp microscope and photographed during the treatment course. Results: Epithelial defects in 5 of the 7 affected eyes (71%) responded to PHSRN treatment as manifested by complete epithelial resurfacing within the 4-week period after treatment initiation. The mean ± SD time required for complete epithelial resurfacing in the 5 responding subjects was 15.8 ± 3.4 days. No adverse effects of treatment were observed in any of the subjects. Conclusions: Eye drops containing the fibronectin-derived PHSRN peptide are clinically efficacious for the treatment of PEDs.

AB - Purpose: We have previously shown that the fibronectin-derived peptide PHSRN (Pro-His-Ser-Arg-Asn) promotes corneal epithelial wound healing in vivo. We have now examined the clinical efficacy of eye drops containing the PHSRN peptide for treatment of persistent epithelial defects (PEDs) of the cornea. Methods: Seven patients (5 men and 2 women; mean age ± SD, 78.3 ± 9.4 years) with PEDs were treated by administration of eye drops containing PHSRN. The duration of the PEDs before treatment was 7.4 ± 5.5 weeks. The eye drops were administered as 1 drop per eye 4 times a day. Epithelial defects were observed with a slit-lamp microscope and photographed during the treatment course. Results: Epithelial defects in 5 of the 7 affected eyes (71%) responded to PHSRN treatment as manifested by complete epithelial resurfacing within the 4-week period after treatment initiation. The mean ± SD time required for complete epithelial resurfacing in the 5 responding subjects was 15.8 ± 3.4 days. No adverse effects of treatment were observed in any of the subjects. Conclusions: Eye drops containing the fibronectin-derived PHSRN peptide are clinically efficacious for the treatment of PEDs.

UR - http://www.scopus.com/inward/record.url?scp=84866740562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866740562&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e31824afd6c

DO - 10.1097/ICO.0b013e31824afd6c

M3 - Article

C2 - 23135532

AN - SCOPUS:84866740562

VL - 31

SP - 1408

EP - 1413

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 12

ER -